JP7635165B2 - p53におけるR175H又はY220C変異を認識するT細胞受容体 - Google Patents

p53におけるR175H又はY220C変異を認識するT細胞受容体 Download PDF

Info

Publication number
JP7635165B2
JP7635165B2 JP2021576970A JP2021576970A JP7635165B2 JP 7635165 B2 JP7635165 B2 JP 7635165B2 JP 2021576970 A JP2021576970 A JP 2021576970A JP 2021576970 A JP2021576970 A JP 2021576970A JP 7635165 B2 JP7635165 B2 JP 7635165B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
tcr
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021576970A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022538148A5 (cg-RX-API-DMAC7.html
JP2022538148A (ja
Inventor
シー. デニガー、ドリュー
マレクザデ、パリサ
エー. ローゼンバーグ、スティーヴン
パセット、アンナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of JP2022538148A publication Critical patent/JP2022538148A/ja
Publication of JP2022538148A5 publication Critical patent/JP2022538148A5/ja
Priority to JP2025020882A priority Critical patent/JP2025081413A/ja
Application granted granted Critical
Publication of JP7635165B2 publication Critical patent/JP7635165B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4748—Details p53
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Oncology (AREA)
JP2021576970A 2019-06-27 2020-06-26 p53におけるR175H又はY220C変異を認識するT細胞受容体 Active JP7635165B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025020882A JP2025081413A (ja) 2019-06-27 2025-02-12 p53におけるR175H又はY220C変異を認識するT細胞受容体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962867619P 2019-06-27 2019-06-27
US62/867,619 2019-06-27
PCT/US2020/039785 WO2020264269A1 (en) 2019-06-27 2020-06-26 T cell receptors recognizing r175h or y220c mutation in p53

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025020882A Division JP2025081413A (ja) 2019-06-27 2025-02-12 p53におけるR175H又はY220C変異を認識するT細胞受容体

Publications (3)

Publication Number Publication Date
JP2022538148A JP2022538148A (ja) 2022-08-31
JP2022538148A5 JP2022538148A5 (cg-RX-API-DMAC7.html) 2023-06-29
JP7635165B2 true JP7635165B2 (ja) 2025-02-25

Family

ID=71662353

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021576970A Active JP7635165B2 (ja) 2019-06-27 2020-06-26 p53におけるR175H又はY220C変異を認識するT細胞受容体
JP2025020882A Pending JP2025081413A (ja) 2019-06-27 2025-02-12 p53におけるR175H又はY220C変異を認識するT細胞受容体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025020882A Pending JP2025081413A (ja) 2019-06-27 2025-02-12 p53におけるR175H又はY220C変異を認識するT細胞受容体

Country Status (11)

Country Link
US (1) US12479902B2 (cg-RX-API-DMAC7.html)
EP (1) EP3990481A1 (cg-RX-API-DMAC7.html)
JP (2) JP7635165B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220047969A (cg-RX-API-DMAC7.html)
CN (1) CN114341171A (cg-RX-API-DMAC7.html)
AU (1) AU2020308004B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021026408A2 (cg-RX-API-DMAC7.html)
CA (1) CA3144070A1 (cg-RX-API-DMAC7.html)
MX (2) MX2021015877A (cg-RX-API-DMAC7.html)
TW (2) TW202525841A (cg-RX-API-DMAC7.html)
WO (1) WO2020264269A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019077062A1 (en) * 2017-10-18 2019-04-25 Vivia Biotech, S.L. C-CELLS ACTIVATED BY BIT
JP2024507929A (ja) 2021-02-25 2024-02-21 アラウノス セラピューティクス インコーポレイテッド 多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法
WO2022232599A1 (en) * 2021-04-30 2022-11-03 Regents Of The University Of Minnesota Mesothelin-specific t cell receptors and methods of using same
AU2022271195A1 (en) * 2021-05-03 2023-11-02 Bluesphere Bio, Inc. T cell receptors (tcrs) targeting minor histocompatibility antigen ha-1
EP4334340A1 (en) * 2021-05-07 2024-03-13 The United States of America, as represented by the Secretary, Department of Health and Human Services T cell receptors recognizing c135y, r175h, or m237i mutation in p53
WO2023060195A1 (en) * 2021-10-08 2023-04-13 Baylor College Of Medicine Targeting common somatic mutations in breast cancer with neo-antigen specific adoptive t cell therapy
EP4423143A4 (en) * 2021-10-29 2025-10-01 Yafei Hou T CELL RECEPTOR RECOGNIZING R175H MUTATION IN P53 AND ITS APPLICATION
WO2023150562A1 (en) 2022-02-01 2023-08-10 Alaunos Therapeutics, Inc. Methods for activation and expansion of t cells
WO2024076692A1 (en) * 2022-10-05 2024-04-11 Icahn School Of Medicine At Mount Sinai Heterobifunctional compounds as p53 acetylators
WO2024163371A1 (en) * 2023-01-30 2024-08-08 Fred Hutchinson Cancer Center Binding proteins specific for mutant p53 and uses thereof
AU2024241888A1 (en) 2023-03-27 2025-10-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting y220c or r175h mutation in p53
WO2024220520A2 (en) * 2023-04-21 2024-10-24 Board Of Regents, The University Of Texas System T-cell receptors targeting her2 and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019067242A1 (en) 2017-09-29 2019-04-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services METHODS FOR ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR SPECIFIC MUTATION OF CANCER P53
WO2019067243A1 (en) 2017-09-29 2019-04-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T CELL RECEPTORS RECOGNIZING P53 MUTE

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
PT3149031T (pt) 2014-05-29 2020-03-25 Us Health Receptores de células t anti-e7 do papilomavírus humano 16
EP3770168A1 (en) 2015-05-18 2021-01-27 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
CN107748893A (zh) * 2017-09-29 2018-03-02 阿里巴巴集团控股有限公司 提升车辆定损图像识别结果的方法、装置及服务器
EP4334340A1 (en) 2021-05-07 2024-03-13 The United States of America, as represented by the Secretary, Department of Health and Human Services T cell receptors recognizing c135y, r175h, or m237i mutation in p53
AU2024241888A1 (en) 2023-03-27 2025-10-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting y220c or r175h mutation in p53

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019067242A1 (en) 2017-09-29 2019-04-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services METHODS FOR ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR SPECIFIC MUTATION OF CANCER P53
WO2019067243A1 (en) 2017-09-29 2019-04-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T CELL RECEPTORS RECOGNIZING P53 MUTE

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DENIGER, Drew C. et al.,Clinical Cancer Research,2018年,Vol. 24, No. 22,p.5562-5573,DOI:10.1158/1078-0432.CCR-18-0573

Also Published As

Publication number Publication date
EP3990481A1 (en) 2022-05-04
US12479902B2 (en) 2025-11-25
MX2026003696A (es) 2026-06-01
BR112021026408A2 (pt) 2022-02-08
WO2020264269A1 (en) 2020-12-30
KR20220047969A (ko) 2022-04-19
MX2021015877A (es) 2022-04-18
TWI908730B (zh) 2025-12-21
JP2025081413A (ja) 2025-05-27
TW202525841A (zh) 2025-07-01
US20220332785A1 (en) 2022-10-20
AU2020308004A1 (en) 2022-02-03
AU2020308004B2 (en) 2026-03-19
TW202108609A (zh) 2021-03-01
CN114341171A (zh) 2022-04-12
JP2022538148A (ja) 2022-08-31
CA3144070A1 (en) 2020-12-30

Similar Documents

Publication Publication Date Title
US20230026180A1 (en) Hla class i-restricted t cell receptors against mutated ras
US12479902B2 (en) T cell receptors recognizing R175H or Y220C mutation in P53
US11352410B2 (en) Anti-KK-LC-1 T cell receptors
US20230080742A1 (en) Hla class i-restricted t cell receptors against ras with g12d mutation
US20240254190A1 (en) T cell receptors recognizing c135y, r175h, or m237i mutation in p53
EP3870603A1 (en) Hla-a3-restricted t cell receptors against mutated ras
US20230159614A1 (en) Hla class ii-restricted t cell receptors against ras with g12v mutation
EP3218404B1 (en) Human anti-thyroglobulin t cell receptors
US20230321240A1 (en) T cell receptors recognizing r273c or y220c mutations in p53
US20230257440A1 (en) Hla class ii-restricted drb t cell receptors against ras with g12v mutation
RU2830061C2 (ru) T-клеточные рецепторы, распознающие мутацию r175h или y220c в p53
EP4326751A1 (en) Hla class i-restricted t cell receptors against ras with q61k mutation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220412

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20220412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230621

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240911

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250212

R150 Certificate of patent or registration of utility model

Ref document number: 7635165

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150